The BCL2 inhibitor Venetoclax has been studied in combination with the BCL-X and BCL-2 inhibitor Navitoclax in a phase 1 study in children and adults with relapsed/refractory ALL, of which, 19 patients had T-ALL [131]. The gene discussed is BCL2L1; the disease is acute lymphoblastic leukemia.